Ilka Thomsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilka Thomsen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Achim Krüger
Institute of Experimental Oncology and Therapy Research, Technical University of Munich, School of Medicine, Munich, Germany
1 shared publication - Boris Strilic
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany
1 shared publication - Christian Röder
Institute of Applied Physics, Faculty of Chemistry and Physics, Technische Universität Bergakademie Freiberg, Leipziger Straße 23, 09599 Freiberg, Germany
1 shared publication - Christoph Becker-Pauly
Biochemical Institute, Christian-Albrechts-University of Kiel, Kiel, Germany
1 shared publication - Clemens Schafmayer
Department of General, Visceral, Vascular, Thoracic, and Transplant Surgery, University Hospital Rostock, Rostock, Germany
1 shared publication - Dieter Adam
Institut für Immunologie, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
1 shared publication
Latest Publications
- Open Access
- 17 December 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (1)
Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis
Metastasis is the major cause of death in cancer patients. Circulating tumor cells need to migrate through the endothelial layer of blood vessels to escape the hostile circulation and establish metastases at distant organ sites. Here, we identified the membrane-bound metalloprotease ADAM17 on endothelial cells as a key driver of metastasis. We show that TNFR1-dependent tumor cell–induced endothelial cell death, tumor cell extravasation, and subsequent metastatic seeding is dependent on the activity of endothelial ADAM17. Moreover, we reveal that ADAM17-mediated TNFR1 ectodomain shedding and subsequent processing by the γ-secretase complex is required for the induction of TNF-induced necroptosis. Consequently, genetic ablation of ADAM17 in endothelial cells as well as short-term pharmacological inhibition of ADAM17 prevents long-term metastases formation in the lung. Thus, our data identified ADAM17 as a novel essential regulator of necroptosis and as a new promising target for antimetastatic and advanced-stage cancer therapies.
- 17 December 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (1)
Open AccessInhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis
Metastasis is the major cause of death in cancer patients. Circulating tumor cells need to migrate through the endothelial layer of blood vessels to escape the hostile circulation and establish metastases at distant organ sites. Here, we identified the membrane-bound metalloprotease ADAM17 on endothelial cells as a key driver of metastasis. We show that TNFR1-dependent tumor cell–induced endothelial cell death, tumor cell extravasation, and subsequent metastatic seeding is dependent on the activity of endothelial ADAM17. Moreover, we reveal that ADAM17-mediated TNFR1 ectodomain shedding and subsequent processing by the γ-secretase complex is required for the induction of TNF-induced necroptosis. Consequently, genetic ablation of ADAM17 in endothelial cells as well as short-term pharmacological inhibition of ADAM17 prevents long-term metastases formation in the lung. Thus, our data identified ADAM17 as a novel essential regulator of necroptosis and as a new promising target for antimetastatic and advanced-stage cancer therapies.